Showing results (551-560 of 688) with videos related to
Sort By:
Pageof 69
ACR Open Rheumatology|July 26, 2020
Long-Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled TrialsPhilip J Mease, Dafna D Gladman, Juan J Gomez-Reino, et al.Nephron. Clinical Practice|July 8, 2010
Measuring the glomerular filtration rate in obese individuals without overt kidney diseaseAllon N Friedman, Matthew Strother, Sara K Quinney, et al.ACR Open Rheumatology|June 23, 2022
Certolizumab Pegol Efficacy in Patients With Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status: An Analysis From the C-axSpAnd StudyPhilip C Robinson, Walter P Maksymowych, Lianne S Gensler, et al.The Lancet. Rheumatology|January 25, 2024
Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 studyIain B McInnes, Philip J Mease, Alan J Kivitz, et al.Medicine|August 20, 2015
A Population-Based Study of 30-day Incidence of Ischemic Stroke Following Surgical Neck DissectionS Danielle MacNeil, Kuan Liu, Amit X Garg, et al.Annals of the Rheumatic Diseases|May 7, 2010
Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD studyEdward Keystone, Mark C Genovese, Lars Klareskog, et al.Rheumatology (Oxford, England)|December 13, 2021
Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 programCharles G Peterfy, Vibeke Strand, Alan Friedman, et al.Communications Biology|October 26, 2025
Early gigantic lamniform marks the onset of mega-body size in modern shark evolutionMohamad Bazzi, Mikael Siversson, Sabine Wintner, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 14, 2011
Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation?Franziska A Stressmann, Geraint B Rogers, Peter Marsh, et al.The Lancet. Rheumatology|January 27, 2024
Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension studyPeter Nash, Laura C Coates, Dona Fleishaker, et al.Pageof 69